Listening to patient-reported outcomes, especially in clinical trials, is extremely important, especially the array of technology available to collect this information, said Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing.
Listening to patient-reported outcomes, especially in clinical trials, is extremely important, especially the array of technology available to collect this information, said Sophia K. Smith, PhD, MSW, associate professor at the Duke School of Nursing.
Transcript (modified)
Can the introduction of patient-centeredness in clinical trials, such as measures of patient-reported outcomes (PROs), be considered palliative care?
I’m a big proponent of hearing from the patient. I think PROs are extremely important, particularly in clinical trials. There’s different ways to collect this information. I think that we should really look at technology to help leverage that with electronic patient-reported outcomes systems
I know that a lot of our medical systems have electronic health records now, such as Epic, and they actually have survey capability built in. There’s other tools such as Apple Research Kit, where we can provide surveys on mobile devices, so a lot of our patients, particularly our younger patients and our patients who may use their smartphone as their only connection to the internet, being able to put these PROs out there for them to use on their mobile devices is really important.
I am also a big proponent of the distress thermometers, so you could probably characterize that as a PRO, but each time our cancer patients come in for their treatment or a visit we ask them how distressed they are and then we list a series of areas that they might be distressed in. For example, financial distress, emotional distress, maybe relationship problems, maybe some spiritual crisis. So that’s another form of PROs and, again, as early in the process as you can introduce these things the better.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More